Last reviewed · How we verify
Companion Tablet
Companion Tablet is an antiparasitic agent developed for treatment of parasitic infections.
Companion Tablet is an antiparasitic agent developed for treatment of parasitic infections. Used for Parasitic infection (specific indication not publicly disclosed).
At a glance
| Generic name | Companion Tablet |
|---|---|
| Also known as | Chinese-made praziquantel |
| Sponsor | Jiangsu Institute of Parasitic Diseases |
| Modality | Small molecule |
| Therapeutic area | Parasitology/Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The drug is developed by the Jiangsu Institute of Parasitic Diseases, a leading research institution focused on parasitic disease therapeutics. While specific molecular targets are not publicly detailed, the drug is in Phase 3 development, indicating it has demonstrated sufficient efficacy and safety in earlier trials to warrant late-stage clinical evaluation for parasitic disease indications.
Approved indications
- Parasitic infection (specific indication not publicly disclosed)
Common side effects
Key clinical trials
- Supportive Care Intervention for Outpatient Stem Cell Transplant Patients (NA)
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (PHASE2)
- Health, Aging and Later-Life Outcomes (NA)
- Virtual Reality for Pain and Anxiety Relief in Labor (NA)
- Talk-to-Jo" Intelligent Digital Health Companion, Neurocognitive Disorders and Dyads
- CLEAR Care Companion Application (NA)
- Contactless Vital Signs Measurement Study (CVMS)
- Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Companion Tablet CI brief — competitive landscape report
- Companion Tablet updates RSS · CI watch RSS
- Jiangsu Institute of Parasitic Diseases portfolio CI